临床级间充质干细胞外泌体SNE-101的多重心血管抗动脉粥样硬化效应
该研究在ApoE-/-小鼠高脂饮食模型中每周静脉注射SNE-101(6×10⁸颗粒)共4周,发现其可减轻主动脉斑块负荷、炎症和肝脂肪变性,并改善血脂谱(降低LDL-C、甘油三酯、PCSK9和Lp(a),P<0.050)。体外实验显示SNE-101通过上调PPARγ/LXRα/ABCA1/ABCG1轴促进胆固醇外流。
要点
- SNE-101减轻ApoE-/-小鼠主动脉斑块负荷和炎症
- SNE-101降低LDL-C、甘油三酯、PCSK9和Lp(a)水平
- 机制涉及上调PPARγ/LXRα/ABCA1/ABCG1轴促进胆固醇外流
核心结论
- 间充质干细胞外泌体SNE-101是动脉粥样硬化的有前景治疗策略,通过增强胆固醇外流、抑制PCSK9和Lp(a)及减轻全身炎症来应对心血管风险。
研究设计与样本
- ApoE-/-雄性小鼠6-8周龄,每组n=6,高脂饮食,SNE-101(6×10⁸颗粒)每周尾静脉注射一次共4周。
- 体外泡沫细胞实验评估胆固醇外流。
主要发现
- 体外SNE-101显著减少脂质积累并通过上调PPARγ/LXRα/ABCA1/ABCG1轴增强胆固醇外流(P<0.050)。
- ApoE-/-小鼠中SNE-101减轻主动脉斑块负荷、炎症和肝脂肪变性。
- SNE-101显著改善全身血脂谱,降低LDL-C、甘油三酯、PCSK9和Lp(a)水平(P<0.050),并恢复肝脏LDL-R表达。
临床怎么用
- SNE-101已获批用于急性缺血性卒中试验,本机制研究为其在卒中临床试验中的应用提供依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atherosclerosis remains a leading cause of cardiovascular diseases. Despite current lipid-lowering therapies, residual risk persists due to inflammation and elevated Lp(a) (lipoprotein[a]) levels. Mesenchymal stem cell-derived extracellular vesicles show promise as a novel therapeutic modality. This hypothesis-testing (new) study investigated the antiatherosclerotic effect and systemic lipid-modulating potential of the clinical-grade mesenchymal stem cell-derived extracellular vesicle product SNE-101, which is currently approved for acute ischemic stroke trials. METHODS: ApoE-/- (apolipoprotein E-deficient) mice (male, 6-8 weeks old; n=6 per group) were placed on a high-fat diet, and SNE-101 (6×10⁸ particles) was administered intravenously via the tail vein once weekly for 4 weeks. The primary exposure variable was SNE-101 treatment, and the primary outcome variable was aortic plaque burden, quantified as the percentage of Oil Red O-stained area. In vitro foam cell assays were performed to assess cholesterol efflux. RESULTS: In vitro, SNE-101 significantly reduced lipid accumulation and enhanced cholesterol efflux via upregulation of the PPARγ (peroxisome proliferator-activated receptor gamma)/LXRα (liver X receptor alpha)/ABCA1 (ATP-binding cassette transporter A1)/ABCgG1 (ATP-binding cassette transporter G1) axis (P<0.050). In ApoE-/- mice, SNE-101 attenuated aortic plaque burden, inflammation, and hepatic steatosis. Extracellular vesicle treatment significantly improved systemic lipid profiles by reducing LDL-C (low-density lipoprotein-cholesterol), triglyceride, PCSK9 (proprotein convertase subtilisin/kexin type 9), and Lp(a) levels (P<0.050) while restoring hepatic LDL-R (low-density lipoprotein-cholesterol) expression. CONCLUSIONS: Mesenchymal stem cell-derived extracellular vesicles (SNE-101) represent a promising therapeutic strategy for atherosclerosis. By enhancing cholesterol efflux, suppressing PCSK9 and Lp(a), and reducing systemic inflammation, SNE-101 addresses critical cardiovascular risks. This provides strong mechanistic guidance for its application in ongoing clinical trials for acute ischemic stroke.
引用
- Kim J, Park D, Yoo J, et al. Multimodal Antiatherosclerotic Effects of Clinical-Grade Mesenchymal Stem Cell-Derived Extracellular Vesicles. Stroke. 2026. PMID: 41503702. doi:10.1161/STROKEAHA.125.052894
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。